These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24319080)

  • 21. Bleeding with dabigatran (Pradaxa).
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98. PubMed ID: 22173427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
    Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Kent AP; Pogue J; Spahr J; Clemens A; Noack H; Diener HC; Wallentin L; Yusuf S; Connolly SJ
    Europace; 2016 Jul; 18(7):973-8. PubMed ID: 26944733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
    Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
    Samama CM; Rosencher N; Kleine E; Feuring M; Brueckmann M; Clemens A; Gullberg J; Frostick SP
    Thromb Res; 2016 Jul; 143():103-10. PubMed ID: 27208980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
    Stabile E; Izzo R; Rozza F; Losi MA; Coscioni E; Trimarco B
    High Blood Press Cardiovasc Prev; 2016 Jun; 23(2):115-22. PubMed ID: 27207360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation.
    Antoniou T; Macdonald EM; Yao Z; Hollands S; Gomes T; Tadrous M; Mamdani MM; Juurlink DN;
    CMAJ; 2017 Jan; 189(1):E4-E10. PubMed ID: 28246253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
    Wang H; Zhou Y; Rong G; Lu L; Zhang J
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):563-7. PubMed ID: 26881855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation.
    Yavuz B; Ayturk M; Ozkan S; Ozturk M; Topaloglu C; Aksoy H; Şabanoglu C; Tanalp AC; Dal K; Ata N; Yavuz BB
    J Thromb Thrombolysis; 2016 Oct; 42(3):399-404. PubMed ID: 27085540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
    Beshir SA; Chee KH; Lo YL
    Int J Clin Pharm; 2016 Oct; 38(5):1182-90. PubMed ID: 27450507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose tailoring of dabigatran etexilate: obvious or excessive?
    Douxfils J; Mullier F; Dogné JM
    Expert Opin Drug Saf; 2015 Aug; 14(8):1283-9. PubMed ID: 25994994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
    Molteni M; Bo M; Di Minno G; Di Pasquale G; Genovesi S; Toni D; Verdecchia P
    Intern Emerg Med; 2017 Jun; 12(4):425-435. PubMed ID: 28439778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding incidence and real-life prescribing practices with dabigatran use in an acute care setting.
    Tran TH; Nguyen C; Lam T; Campbell P
    Consult Pharm; 2014 Nov; 29(11):735-40. PubMed ID: 25369188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.
    Fieland D; Taylor M
    Ann Pharmacother; 2012 Jan; 46(1):e3. PubMed ID: 22202498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
    J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
    Fukaya H; Niwano S; Oikawa J; Nishinarita R; Horiguchi A; Nakamura H; Fujiishi T; Igarashi T; Ishizue N; Yoshizawa T; Satoh A; Kishihara J; Murakami M; Ako J
    J Cardiol; 2017 Mar; 69(3):591-595. PubMed ID: 27377855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation: A meta analysis of adjusted analysis in routine practice settings.
    Darwiche W; Bejan-Angoulvant T; Dievart F; Babuty D; Angoulvant D; Fauchier L
    Int J Cardiol; 2016 Mar; 206():89-92. PubMed ID: 26785030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.